BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xu F, Wang KY, Wang N, Li G, Liu D. Modified human glucagon-like peptide-1 (GLP-1) produced in E. coli has a long-acting therapeutic effect in type 2 diabetic mice. PLoS One 2017;12:e0181939. [PMID: 28750064 DOI: 10.1371/journal.pone.0181939] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 Icart LP, Souza FG Jr, Lima LMTR. Polymeric microparticle systems for modified release of glucagon-like-peptide-1 receptor agonists. J Microencapsul 2021;38:249-61. [PMID: 33586588 DOI: 10.1080/02652048.2021.1889059] [Reference Citation Analysis]
2 Yue Z, Zhang L, Li C, Chen Y, Tai Y, Shen Y, Sun Z. Advances and potential of gene therapy for type 2 diabetes mellitus. Biotechnology & Biotechnological Equipment 2019;33:1150-7. [DOI: 10.1080/13102818.2019.1643783] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
3 Tasyurek HM, Altunbas HA, Balci MK, Griffith TS, Sanlioglu S. Therapeutic Potential of Lentivirus-Mediated Glucagon-Like Peptide-1 Gene Therapy for Diabetes. Hum Gene Ther. 2018;29:802-815. [PMID: 29409356 DOI: 10.1089/hum.2017.180] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]